2. Signaling Pathways
  3. GPCR/G Protein
  4. P2Y Receptor

P2Y Receptor

P2Y Receptor

Related Products

PDF 0.7 MB

P2Y receptors are a class of G protein-coupled receptors (GPCRs) activated by extracellular nucleotides (ATP, UTP, and UDP). There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain.

The P2Y family can be further divided into a subfamily of five P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11Rs (“P2Y1-like”) that stimulate phospholipase C (PLC) through Gq protein and a second subfamily of P2Y12, P2Y13, and P2Y14Rs (“P2Y12-like”) that inhibit adenylate cyclase through Gi protein. Other effector pathways have been documented, such as coupling of the P2Y11R to Gs as well as to Gq in some cells to induce stimulation of cyclic AMP production.

P2Y Receptor Isoform Specific Products:

P2Y Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-108656A
    MRS2365 trisodium
    		Agonist ≥99.0%
    MRS2365 trisodium is a potent and selective P2Y1 receptor (EC50=0.4 nM)/[35S]GTPγS binding/β-arrestin 2 recruitment agonist. MRS2365 trisodium relieves mechanical allodynia and increases mechanical sensitivity.
    MRS2365 trisodium
  • HY-108657A
    MRS2279 diammonium
    		Antagonist ≥98.0%
    MRS2279 diammonium is a selective and high affinity P2Y1 receptor antagonist, with a Ki value of 2.5 nM and an IC50 value of 51.6 nM. MRS2279 diammonium competitively inhibits ADP-promoted platelet aggregation with an pKb value of 8.05.
    MRS2279 diammonium
  • HY-101308
    MRS2179 tetrasodium
    		Antagonist
    MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors. MRS2179 tetrasodium inhibits platelet aggregation.
    MRS2179 tetrasodium
  • HY-15284S1
    Prasugrel-d3
    		Inhibitor 98.58%
    Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
    Prasugrel-d<sub>3</sub>
  • HY-108649A
    MRS2768 tetrasodium salt
    		Agonist 98.70%
    MRS2768 tetrasodium salt is a moderately potent and selective P2Y2 receptor agonist. MRS2768 tetrasodium salt has a protective effect on cardiomyocytes from ischemic damage in vivo and in vitro.
    MRS2768 tetrasodium salt
  • HY-123669
    R-138727
    		Inhibitor
    R-138727, the thiol-containing active metabolite of Prasugrel, is an irreversible platelet P2Y12 receptor inhibitor. R-138727 inhibits ADP-induced platelet aggregation.
    R-138727
  • HY-125989B
    2-Methylthio-AMP diTEA
    		Antagonist ≥98.0%
    2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation.
    2-Methylthio-AMP diTEA
  • HY-N7032S1
    Uridine 5′-diphosphoglucose-13C6 disodium
    		98.35%
    Uridine 5′-diphosphoglucose-13C6 (disodium) is the 13C labeled Uridine 5′-diphosphoglucose disodium salt[1]. Uridine 5′-diphosphoglucose disodium salt (UDP-D-Glucose disodium salt) is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine-5′-diphosphoglucose is an agonist of the P2Y14 receptor, a neuroimmune system GPCR[2].
    Uridine 5′-diphosphoglucose-<sup>13</sup>C<sub>6</sub> disodium
  • HY-N7740
    Adenosine 2',5'-diphosphate sodium
    		Antagonist ≥99.0%
    Adenosine 2',5'-diphosphate sodium is a competitive P2Y1 antagonist. Adenosine 2',5'-diphosphate sodium exhibits non-selective antagonism at recombinant and human platelet P2X1 receptors.
    Adenosine 2',5'-diphosphate sodium
  • HY-113044
    Uridine diphosphate glucose
    		Agonist
    Uridine diphosphate glucose is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine diphosphate glucose is an agonist of the P2Y14 receptor, a neuroimmune system GPCR1.
    Uridine diphosphate glucose
  • HY-111755
    Oral antiplatelet agent 1
    		Antagonist
    Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders.
    Oral antiplatelet agent 1
  • HY-110322A
    PPTN
    		Antagonist 99.63%
    PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity.
    PPTN
  • HY-19638
    Cangrelor
    		Antagonist
    Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist.
    Cangrelor
  • HY-108661
    NF546
    		Agonist
    NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
    NF546
  • HY-15283AS
    (±)-Clopidogrel-d7 sulfate
    (±)-Clopidogrel-d7 (sulfate) is the deuterium labeled (±)-Clopidogrel sulfate[1].
    (±)-Clopidogrel-d<sub>7</sub> sulfate
  • HY-100254
    TAK-024
    		Inhibitor
    TAK-024 is a platelet inhibitor with IC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.
    TAK-024
  • HY-D1199
    Blue FPG-A trisodium
    		Antagonist
    Blue FPG-A trisodium is a selective antagonist of P2X1 receptor and P2Y1 receptor with IC50 values of 35.5 μM and 2.6 μM, respectively. Blue FPG-A trisodium is a structural isomer of the components of Reactive Blue 2 (RB2).
    Blue FPG-A trisodium
  • HY-17459R
    Clopidogrel hydrogen sulfate (Standard)
    		Inhibitor
    Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor.
    Clopidogrel hydrogen sulfate (Standard)
  • HY-146499
    Antiplatelet agent 2
    		Inhibitor
    Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation.
    Antiplatelet agent 2
  • HY-134361
    ATP-γ-S tetrasodium
    		Agonist
    ATP-γ-S tetrasodium, an ATP analogue, is a P2Y11 receptor agonist. ATP-γ-S tetrasodium is active in ATP hydrolysis. ATP-γ-S tetrasodium is also an antioxidant and neuroprotectant.
    ATP-γ-S tetrasodium
Cat. No. Product Name / Synonyms Application Reactivity
P2Y Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.